Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 119.78M P/E - EPS this Y -32.40% Ern Qtrly Grth -
Income -28.12M Forward P/E -2.96 EPS next Y -20.40% 50D Avg Chg -13.00%
Sales 6.59M PEG - EPS past 5Y - 200D Avg Chg -30.00%
Dividend N/A Price/Book 2.03 EPS next 5Y - 52W High Chg -62.00%
Recommedations 2.00 Quick Ratio 3.51 Shares Outstanding 81.35M 52W Low Chg 105.00%
Insider Own 18.87% ROA -14.06% Shares Float 57.49M Beta 0.25
Inst Own 40.34% ROE -51.33% Shares Shorted/Prior 241.52K/272.13K Price 1.48
Gross Margin 100.00% Profit Margin - Avg. Volume 328,970 Target Price 4.25
Oper. Margin -280.12% Earnings Date May 14 Volume 316,766 Change -8.07%
About ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V. News
04/23/24 ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
04/22/24 ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
04/19/24 ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
03/14/24 ProQR Therapeutics Full Year 2023 Earnings: Misses Expectations
03/13/24 ProQR Announces Year End 2023 Operating and Financial Results
02/15/24 ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
01/19/24 ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
01/15/24 While institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the most
01/05/24 ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
12/28/23 Is ProQR (PRQR) Stock a Solid Choice Right Now?
12/08/23 ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
11/07/23 ProQR Announces Third Quarter 2023 Operating and Financial Results
11/06/23 ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
09/28/23 ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
09/27/23 ProQR Therapeutics Provides Update on Ophthalmic Assets
09/07/23 ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
08/08/23 ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions
08/03/23 ProQR Announces Second Quarter 2023 Operating and Financial Results
08/01/23 ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
07/06/23 ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
PRQR Chatroom

User Image dirkfrank Posted - 11 hours ago

$PRQR

User Image Pandanmonium Posted - 14 hours ago

$PRQR anything under 2 is a steal…

User Image cayman777 Posted - 1 day ago

$PRQR -Lilly and Prqr presenting separate data side by side at the same rnai conference is a good signal of a continued strong partnership .

User Image justfacts1 Posted - 1 day ago

$PRQR manipulation continues.

User Image dirkfrank Posted - 1 day ago

$PRQR when thet are down. Everyone and everything is down.

User Image justfacts1 Posted - 2 days ago

$PRQR news pending?

User Image valueforme Posted - 3 days ago

$PRQR Adding ALNY Research SVP to the board of directors shows you what ProQR cares about - research. Not business, but research.

User Image Longroader Posted - 3 days ago

$PRQR 3 years of silence, finally 1 poster. This AGM, shareholders must push for more data.

User Image Stock_Titan Posted - 3 days ago

$PRQR ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 https://www.stocktitan.net/news/PRQR/pro-qr-nominates-martin-maier-ph-d-to-board-and-announces-annual-1mcl4t7fmlh9.html

User Image cayman777 Posted - 4 days ago

$PRQR -Two pre clinical data updates by Prqr and Lilly on May 8th.

User Image valueforme Posted - 4 days ago

$PRQR Lilly is going to talk

User Image Stock_Titan Posted - 4 days ago

$PRQR ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting https://www.stocktitan.net/news/PRQR/pro-qr-highlights-upcoming-presentations-on-axiomer-rna-editing-at-679t8t038hal.html

User Image cayman777 Posted - 4 days ago

$PRQR -Right back to their algo manipulation. They rarely take a day off here.

User Image johnnygogogo Posted - 4 days ago

$PRQR what would be a reasonable, ie. very conservative royalty that ProQR could command from every competitor that successfully gets an ADAR-based drug across the finish line? 7%? 10%? 12%? All it will take is one competitor to belly up to the bar and strike a deal for price discovery (and precedent). Start adding up the enterprise value of its competitors $WVE $KRRO Shape (private), ADARx (private), etc.

User Image Longroader Posted - 4 days ago

$PRQR All eyes on $LLY post strawmen challenges. Can easily go to $5 if $LLY exercises its options. Sitryx is a good case study. https://www.sitryx.com/news/sitryx-announces-partner-lilly-exercises-option-to-sit-011-for-chronic-autoimmune-and-inflammatory-diseases

User Image valueforme Posted - 1 week ago

$PRQR ProQR keeps fighting with Dicerna in the patent courts. The more wins they have the higher conviction will Lilly have that it makes sense to buy them . Dicerna is bought by Novo and there is at least one program that Lilly has with them. Historical context https://medwatch.com/News/Pharma___Biotech/article13482239.ece

User Image cayman777 Posted - 1 week ago

$PRQR -Ev of ~ $25 million here is an absolute joke.

User Image LeftyT Posted - 1 week ago

$PRQR picked up 500 more shares atm and paid 1.9199 for them. Love the way the patent challenge is holding up. BP is trying to find an opening, but it looks like all roads lead to PRQR's ADAR approach. GLTA longs!!!

User Image Longroader Posted - 1 week ago

$PRQR Maybe the last shall be the first? https://www.nature.com/articles/d41573-024-00070-y

User Image skeezbag Posted - 1 week ago

$PRQR balance sheet doing nothing but paying lawyer fees and that's by design with BP

User Image cayman777 Posted - 1 week ago

$PRQR -Someone very interested in the ip here. Continual court challenges.

User Image AZOZ Posted - 1 week ago

$PRQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

User Image Stock_Titan Posted - 1 week ago

$PRQR ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio https://www.stocktitan.net/news/PRQR/pro-qr-achieves-successful-defense-of-new-challenge-to-its-axiomer-8ap6xok2v8qo.html

User Image dirkfrank Posted - 1 week ago

$PRQR I repeat. Biotech is having a hard time. Index testing 4000. 52 wk low 3600. Just 10% to go.

User Image Longroader Posted - 1 week ago

$PRQR Is the usual pattern, rise and rinse folks. Market is valuing nothing about the science yet.

User Image skeezbag Posted - 1 week ago

$PRQR did citigroup just really make a 20cwnt price target increase from 1.8 to 2 Fucking hilarious. Like why even

User Image justfacts1 Posted - 1 week ago

$PRQR long waiting for $LLY news:

User Image cayman777 Posted - 1 week ago

$PRQR -Manipulation as usual.

User Image Pandanmonium Posted - 1 week ago

$PRQR I’m looking at this as a buying opportunity… but keep compressing the diamond that is this stock

User Image Longroader Posted - 1 week ago

$PRQR XBI today down 2%, ytd -4.3%, rocky days. Days below 2s may come. Price way below potential.

Analyst Ratings
Citigroup Neutral Apr 18, 24
HC Wainwright & Co. Buy Mar 14, 24
Chardan Capital Buy Mar 14, 24
Raymond James Outperform Nov 8, 23
Chardan Capital Buy Nov 8, 23
Citigroup Buy Sep 18, 23
HC Wainwright & Co. Buy Aug 7, 23
Chardan Capital Neutral Aug 4, 23
Cantor Fitzgerald Overweight May 17, 23